Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
eupolicy.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
This Mastodon server is a friendly and respectful discussion space for people working in areas related to EU policy. When you request to create an account, please tell us something about you.

Administered by:

Server stats:

244
active users

eupolicy.social: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.6

#prescriptiondrugs

1 post1 participant0 posts today
Public
Bích-Mây Nguyễn :verified:

"She said the filing 'avoids saying anything on the substance at all,' which, she suggested, allows the Trump administration to delay telegraphing its views on mifepristone and to control whether and when it takes action to restrict the drug."

nytimes.com/2025/05/05/health/

The typical medication abortion regimen involves mifepristone, which blocks a hormone needed for pregnancy development and was approved for abortion 25 years ago.
The New York Times · Trump Administration Asks Court to Dismiss Abortion Pill CaseBy Pam Belluck
#healthcare#ReproductiveHealth#ReproductiveJustice
Public
Bích-Mây Nguyễn :verified:

"Klitzman said the issue isn't just about cost or personal choices. 'It's also driven by poor access to healthy food, lack of exercise, income inequality and nonstop junk food marketing,' he said...'You can't solve obesity just by handing out prescriptions...If policymakers start seeing these drugs as a silver bullet, there's a real danger they'll pull back on funding for prevention...'"

newsweek.com/2025/05/09/weight

FEA01_Ozempic_WeightLoss_01
Newsweek · How Weight Loss Drugs Like Ozempic and Mounjaro Are Eating Away at Body PositivityBy Jesus Mesa
#PublicHealth#obesity#PrescriptionDrugs
Public
ResearchBuzz: Firehose

Yale School of Medicine: New Study Finds Online Advertising for Compounded Diabetes and Weight-Loss Drugs May Mislead Consumers. “Online advertising for compounded versions of a popular class of type 2 diabetes and weight-loss medications commonly includes practices that only partially inform or even misinform consumers, a team of Yale School of Medicine (YSM) researchers has found. The work […]

https://rbfirehose.com/2025/03/05/yale-school-of-medicine-new-study-finds-online-advertising-for-compounded-diabetes-and-weight-loss-drugs-may-mislead-consumers-2/

ResearchBuzz: Firehose | Individual posts from ResearchBuzz · Yale School of Medicine: New Study Finds Online Advertising for Compounded Diabetes and Weight-Loss Drugs May Mislead Consumers | ResearchBuzz: Firehose
More from ResearchBuzz: Firehose
#AI#diabetes#drugs
Public
Kim Perales

Many of Trump’s voters will be surprised when they discover that their prescription drug costs have skyrocketed.

“Trump’s Make Drug Prices High Again EO rescinded the BIden-Harris order to lower drug costs - to cap the co-payment for generic medications at $2 for Medicare beneficiaries.”
-S Kennedy

#Medicare #Medicaid #Trump #Health #PrescriptionDrugs #USPol

marketwatch.com/story/trump-ro

Public
Miguel Afonso Caetano

"The Federal Trade Commission today published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ (PBMs) influence over specialty generic drugs, including significant price markups by PBMs for cancer, HIV, and a variety of other critical drugs.

Staff’s latest report found that the ‘Big 3 PBMs’—Caremark Rx, LLC (CVS), Express Scripts, Inc. (ESI), and OptumRx, Inc. (OptumRx)—marked up numerous specialty generic drugs dispensed at their affiliated pharmacies by thousands of percent, and many others by hundreds of percent. Such significant markups allowed the Big 3 PBMs and their affiliated specialty pharmacies to generate more than $7.3 billion in revenue from dispensing drugs in excess of the drugs’ estimated acquisition costs from 2017-2022. The Big 3 PBMs netted such significant revenues all while patient, employer, and other health care plan sponsor payments for drugs steadily increased annually, according to the staff report.

“The FTC staff’s second interim report finds that the three major pharmacy benefit managers hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer,” said FTC Chair Lina M. Khan. “The FTC should keep using its tools to investigate practices that may inflate drug costs, squeeze independent pharmacies, and deprive Americans of affordable, accessible healthcare—and should act swiftly to stop any illegal conduct.”"

ftc.gov/news-events/news/press

Federal Trade Commission · FTC Releases Second Interim Staff Report on Prescription Drug MiddlemenThe Federal Trade Commission today published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ (PBMs) influence over specialty g
#USA#FTC#Healthcare
Public
Bích-Mây Nguyễn :verified:

"The start of the new year is typically a time when people make big changes around health—and drug companies are no exception.

As of Jan. 1, more than 250 branded drugs from pharmaceutical giants including Bristol Myers Squibb, Sanofi-Pasteur, Merck, Pfizer, and more will see price hikes in the U.S., according to data analysis conducted by health care research firm 3 Axis Advisors."

fortune.com/well/2025/01/03/pf

Fortune · Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1By Jennifer Fields
#healthcare#PhRMA#PrescriptionDrugs
Public
Voting is Your POWER

By #Voting for #Democrats We Save OUR LIVES!

In #Minnesota where #Democrats control all 3 branches of state government, a new law goes into effect that Bans Forever Chemicals known as PFAS

Also, in #minnesota health plans will be required to cap co-pays at $25 per one-month supply of prescription drugs used to treat chronic diseases such as diabetes, asthma, and allergies requiring the use of epinephrine auto-injectors #prescriptiondrugs #healthinsurance
#uspol #uspolitics #health #publichealth #environment #diabetes #athsma

Public
Bích-Mây Nguyễn :verified:

"Many of President-elect Donald Trump’s candidates for federal health agencies have promoted policies and goals that put them at odds with one another or with Trump’s choice to run the Department of Health and Human Services, Robert F. Kennedy Jr., setting the stage for internal friction over public health initiatives."

kffhealthnews.org/news/article

KFF Health NewsTrump’s Picks for Top Health Jobs Not Just Team of Rivals but ‘Team of Opponents’ - KFF Health NewsThe president-elect’s choices to lead the Department of Health and Human Services, as well as agencies such as the National Institutes of Health, FDA, and CDC, hold positions on issues including abortion and vaccination that are often at odds.
#healthcare#PublicHealth#abortion
Public
Carolyn Barber, MD

Same Drug, 2,200 DIFFERENT PRICES!! 💰💰💰

“Some 61 drugs had monthly prices that diverged by at least $30K, including a $223K range for nitisinone.

The reason for the huge price differences: PBMs negotiate widely different prices for prescriptions, depending on your insurance plan.

@robertkennedyjr let’s reform this! Wonderful place to start. wsj.com/health/healthcare/medi #press #prescriptiondrugs #medicare

ExploreLive feeds
About